retatrutide ly3437943 clinical trial results (RETA) is one of the most promising investigational peptides in obesity research—but one important question deserves more attention: Can it affect birth control? Current evidence shows that GLP-1 receptor agonists slow Eli Lilly's Phase 3 clinical

The most pronounced improvements in BC were observed after 3 and 6 months of treatment, whereas after 12 months these beneficial effects tended to diminish

Both find themselves reaching for good old-fashioned water

Losing too much of it may compromise metabolic flexibility and longevity

These drugs are also strictly avoided in patients with Multiple Endocrine Neoplasia syndrome type 2 ( MEN 2 ), as animal studies show an increased risk of thyroid C-cell tumors

Methodology and Sources This analysis is based on publicly available sources as of December 26, 2025: FDA communications: Compounding safety alerts, prescribing information, and regulatory guidance Novo Nordisk announcements: Wegovy pill approval, OASIS 4 trial results, pricing disclosures Independent reporting and primary sources: ABC News coverage and Novo Nordisks announcement on December 22, 2025 FDA oral Wegovy approval MEDVi terms and disclosures: Platform structure, pricing, and regulatory disclaimers Key Sources Cited: ABC News: "FDA approves Wegovy pill for weight loss" (December 22, 2025) Novo Nordisk: Official press release on FDA approval and OASIS 4 trial data (December 22, 2025) FDA Safety Communications: 20242025 alerts on compounded semaglutide dosing errors All regulatory references are based on FDA publications and third-party reporting available at the time of publication